Catabasis Pharmaceuticals, Inc. Demonstrates CAT-2003 Lowers Fed And Fasting Triglycerides In Studies Presented At Lipid Conferences

Catabasis Pharmaceuticals Inc. today announced the presentation of clinical and preclinical data demonstrating that CAT-2003 lowers fasting triglycerides in addition to postprandial (fed) triglycerides. The Phase 1 clinical data were presented by Catabasis Chief Medical Officer Joanne Donovan, M.D., Ph.D., at the National Lipid Association (NLA) Scientific Sessions 2014, and the preclinical data were presented by Feng Liu, Ph.D., at the Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions.

Help employers find you! Check out all the jobs and post your resume.